New combo therapy shows promise for advanced throat cancer
NCT ID NCT07248696
First seen Dec 10, 2025 · Last updated May 10, 2026 · Updated 18 times
Summary
This study tests a treatment for people with nasopharyngeal cancer that has spread to other parts of the body. The treatment combines an immunotherapy drug (tislelizumab) with chemotherapy and radiation therapy that is adjusted based on how well the tumor responds. The goal is to see if this approach can help control the cancer and improve survival. The study involves 32 adults aged 18-70 who have not had prior treatment for their cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400000, China
Conditions
Explore the condition pages connected to this study.